Yuanfeng Xia

Executive Director at Changchun Genescience Pharmaceutical Co., Ltd.

Presenter

GenSci is a leading pharmaceutical company in China, with annual sales exceeding $1.5 billion USD in 2023. Building on its core strengths in pediatric and women's health, GenSci has strategically expanded its therapeutic focus into multiple high-impact areas, including endocrinology, oncology and immunology&inflammation (I&I). Leveraging its fully integrated research and development platform, GenSci is commited to advancing cutting-edge therapies that address unmet medical needs and improve patient outcomes across diverse disease landscapes.